Trial Profile
A Nationwide Study Evaluating the Safety and Efficacy of Certolizumab Pegol in a Real World Setting in Psoriatic Arthritis (PsA) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2018
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
- 16 Jun 2018 Results assessing the response and survival of Certolizumab pegol in patients with psoriatic arthritis according to their baseline smoking status and body mass index, presented at the 19th Annual Congress of the European League Against Rheumatism.
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
- 12 Dec 2017 New trial record